La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Haleon Bilan de santé

Santé financière contrôle des critères 2/6

Haleon possède un total de capitaux propres de £16.7B et une dette totale de £8.9B, ce qui porte son ratio d'endettement à 53.4%. Son actif total et son passif total sont £33.4B et de £16.7B. L'EBIT de Haleon est £2.4B ce qui fait que son ratio de couverture des intérêts 6.5. Elle dispose de liquidités et de placements à court terme de £531.0M.

Informations clés

53.4%

Ratio d'endettement

UK£8.93b

Dette

Ratio de couverture des intérêts	6.5x
Argent liquide	UK£531.00m
Fonds propres	UK£16.71b
Total du passif	UK£16.69b
Total des actifs	UK£33.40b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Estimating The Fair Value Of Haleon plc (LON:HLN)

Jun 26

Haleon plc Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 04

Haleon plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 22

Investors Can Find Comfort In Haleon's (LON:HLN) Earnings Quality

Mar 10

Calculating The Fair Value Of Haleon plc (LON:HLN)

Dec 18

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de HLN ( £4.7B ) ne couvrent pas ses passifs à court terme ( £5.6B ).

Passif à long terme: Les actifs à court terme de HLN ( £4.7B ) ne couvrent pas ses passifs à long terme ( £11.1B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de HLN ( 50.3% ) est considéré comme élevé.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de HLN a diminué au cours des 5 dernières années.

Couverture de la dette: La dette de HLN est bien couverte par le flux de trésorerie opérationnel ( 24.6% ).

Couverture des intérêts: Les paiements d'intérêts de HLN sur sa dette sont bien couverts par l'EBIT ( 6.5 x couverture).

Haleon Bilan de santé

Santé financière contrôle des critères 2/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

First half dividend increased to UK£0.02

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Second quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million.

Estimating The Fair Value Of Haleon plc (LON:HLN)

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Haleon plc Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

First quarter 2024 earnings: EPS exceeds analyst expectations

Haleon plc Announces Directorate Change

Now 20% overvalued after recent price rise

Haleon plc Announces Chief Financial Officer Changes

Haleon plc Announces Management Changes

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel'

Upcoming dividend of UK£0.042 per share

Haleon plc's (LON:HLN) Popularity With Investors Is Clear

Final dividend increased to UK£0.042

Haleon plc, Annual General Meeting, May 08, 2024

Now 23% overvalued

Haleon plc Proposes Final Dividend for Fiscal Year 2023, Payable on 16 May 2024

Calculating The Intrinsic Value Of Haleon plc (LON:HLN)

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Haleon (LON:HLN) Might Have The Makings Of A Multi-Bagger

Third quarter 2023 earnings released: EPS: UK£0.04 (vs UK£0.037 in 3Q 2022)

Haleon plc to Report Fiscal Year 2023 Results on Feb 29, 2024

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

Estimating The Intrinsic Value Of Haleon plc (LON:HLN)

Upcoming dividend of UK£0.018 per share at 1.1% yield

Haleon (LON:HLN) Shareholders Will Want The ROCE Trajectory To Continue

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon Reportedly Exploring Sale of Nicotine Gum Business

First quarter 2023 earnings released: EPS: UK£0.042 (vs UK£0.037 in 1Q 2022)

Haleon plc's (LON:HLN) Intrinsic Value Is Potentially 23% Below Its Share Price

High number of new and inexperienced directors

Haleon plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Independent Non-Executive Chair recently bought UK£100k worth of stock

Investors Can Find Comfort In Haleon's (LON:HLN) Earnings Quality

Full year 2022 earnings released: EPS: UK£0.12 (vs UK£0.15 in FY 2021)

Haleon plc Announces Board Changes

Calculating The Fair Value Of Haleon plc (LON:HLN)

Third quarter 2022 earnings released

Haleon plc Provides Revenue Guidance for Fiscal 2022

Second quarter 2022 earnings released

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon Introduces Advil PLUS Acetaminophen to Canadians, Combining Two Trusted Pain Relievers into One Convenient Tablet

Haleon plc to Report First Half, 2022 Results on Sep 19, 2022

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines